Compare LNN & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LNN | ATAI |
|---|---|---|
| Founded | 1954 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.3B |
| IPO Year | 1995 | 2025 |
| Metric | LNN | ATAI |
|---|---|---|
| Price | $109.75 | $4.32 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 8 |
| Target Price | ★ $113.00 | $15.88 |
| AVG Volume (30 Days) | 164.1K | ★ 6.5M |
| Earning Date | 04-02-2026 | 05-11-2026 |
| Dividend Yield | ★ 1.34% | N/A |
| EPS Growth | ★ 12.81 | N/A |
| EPS | ★ 2.70 | N/A |
| Revenue | ★ $676,368,000.00 | $4,089,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.74 | N/A |
| P/E Ratio | $40.90 | ★ N/A |
| Revenue Growth | 11.41 | ★ 1227.60 |
| 52 Week Low | $97.27 | $1.29 |
| 52 Week High | $149.56 | $6.73 |
| Indicator | LNN | ATAI |
|---|---|---|
| Relative Strength Index (RSI) | 45.49 | 55.08 |
| Support Level | $107.45 | $3.41 |
| Resistance Level | $119.95 | $4.68 |
| Average True Range (ATR) | 3.12 | 0.32 |
| MACD | 0.83 | 0.03 |
| Stochastic Oscillator | 55.23 | 38.05 |
Lindsay Corp provides proprietary water management and road infrastructure products and services. It manufactures and distributes agricultural irrigation equipment through two segments: Irrigation and Infrastructure. The Irrigation segment makes center pivot, lateral move, and hose reel irrigation systems and parts. The Infrastructure segment produces barriers, crash cushions, road marking and safety equipment, and railroad signals. The majority of revenue is from the Irrigation segment. The company operates in the United States and international markets, with the majority of revenue coming from the United States.
AtaiBeckley Inc is a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting, and convenient mental health treatments. AtaiBeckley's pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD and EMP-01 ((R)-MDMA HCI) for social anxiety disorder, which are in Phase 2 clinical development.